[Intraperitoneal use of human tumor necrosis factor (hrTNFalfa) in patients with ascites during advanced neoplastic disease].
The results are presented of a clinical trial with the use of hrec TNF alpha administrated intraperitoneally in advanced cancer patients suffering from malignant ascites. Fourteen patients in a terminal phase of a neoplastic disease were treated with intraperitoneal infusions of hr TNF alpha in progressively increasing doses. The procedure was repeated maximum 8 times, with one-week intervals between each dose. Response to the therapy (complete or partial remission) was observed in 8 patients. No evidence was shown of increased survival time in the cancer patients receiving TNF alpha. However, the treatment significantly increased their quality of life, especially in its psychological and somatic aspects.
Muc-Wierzgoń
M
M
Katedra i Klinika Chorób Wewnetrznych Slaskiej Akademii Medycznej.
Madej
K
K
D000368:Aged; D001201:Ascites / Q000209:etiology / Q000628:therapy*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D014409:Tumor Necrosis Factor-alpha
Dootrzewnowe stosowanie ludzkiego rekombinowanego czynnika martwicy nowotworów (hrTNFalfa) u pacjentów z wodobrzuszem wystepujacym w przebiegu zaawansowanej choroby nowotworowej.